drugset / Trial / NCT00545324

First Step With Singulair® Therapy (0476-323)

NCT00545324

Phase 4 Completed 399 enrolled Organon and Co
RandomizedParallel-groupOpen-labelTreatment

Summary

In adult patients with mild persistent asthma, singulair® 10 mg will be at least as effective as low dose Inhaled Corticosteroids (ICS) in improving asthma symptom control or satisfaction over a 6 week comparison period.

Timeline

Start
2002-09
Primary completion
2003-12
Completion
2003-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone Other / unclassified Inhaled
Subject Montelukast Other / unclassified 10 mg

Indications